An artificial peptidomimetic and its preparation method and application

Abstract

The present invention provides an artificial peptidomimetic, the structural formula of which is shown in Formula 1: the present invention also provides a preparation method and application of the artificial peptidomimetic. The preparation method provided by the invention has the advantages of reasonable selection of raw materials, easy availability, simple preparation process and easy industrialization. The artificial peptidomimetic provided by the present invention can be used to prepare drugs for preventing or treating redness and swelling of joints or / and swelling of joints or / and bone erosion or / and joint deformation or / and decrease of joint bone density, and can also be used for Medicines for preventing or treating inflammation-related cytokine IL-1β or / and IL-8 or / and TNF-α are prepared.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an artificial peptide and its preparation method and application. Background technique [0002] Rheumatoid arthritis (rheumatoid arthritis, RA) is a chronic systemic autoimmune disease, mainly causing joint tenderness, swelling and destruction, resulting in disability. The disease is prone to occur in women, and the age is mainly concentrated between 30-50 years old. Worldwide, about 1% of the population suffers from the disease. The lesions of RA are mostly small joints, which have the characteristics of symmetrical distribution. The early clinical symptoms are mainly redness, pain, and limited range of motion. As the disease progresses, the joint mobility gradually decreases, and some patients lose their joint mobility completely. . If the condition is not well controlled, RA may also lead to organ involvement other than joints, such as: keratitis, rheumatoid nodules, pericarditis...

AI Technical Summary

Problems solved by technology

However, RA patients need long-term medication, and the drugs have certain side effects, such as long-term use of non-steroidal anti-inflammatory drugs can induce oral ulcers, drug-induced liver injury (abnormally elevated liver enzymes), abdominal pain, diarrhea, nausea and other symptoms; Long-term use of glucocorticoids in RA patients can increase the risk of cardiovascular disease, diabetes, infection, etc., and have an impact on bone development; antirheumatic drugs, such as methotrexate, have gastrointestinal reactions (mainly manifested as nausea, Vomiting, diarrhea, etc.), bone marrow suppression (leukopenia, skin or internal bleeding), kidney damage and other adverse reactions; biological agents such as infliximab have occurred in clinical trials such as skin rash, headache, nausea, respiratory tract infection, abnormal blood pressure, Adverse events such as elevated transaminases, and the medical expenses of patients using biological agents are 3-5 times the average treatment expenses of the disease, and the economic burden is heavy; herbal preparations, such as tripterygium glycosides tablets, also have vomiting, fatigue, and loss of appetite , abdominal distension, elevated transaminases, white blood cells, thrombocytopenia, oliguria or polyuria, edema, abnormal renal function, palpitations, chest tightness, arrhythmia, dizziness, dizziness and other adverse reactions

Images